1 Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom.
Am J Respir Cell Mol Biol. 2014 Jan;50(1):144-57. doi: 10.1165/rcmb.2013-0142OC.
PAR1 plays a central role in mediating the interplay between coagulation and inflammation, but its role in regulating acute neutrophilic inflammation is unknown. We report that antagonism of PAR1 was highly effective at reducing acute neutrophil accumulation in a mouse model of LPS-induced lung inflammation. PAR1 antagonism also reduced alveolar-capillary barrier disruption in these mice. This protection was associated with a reduction in the expression of the chemokines, CCL2 and CCL7, but not the proinflammatory cytokines, TNF and IL-6, or the classic neutrophil chemoattractants, CXCL1 and CXCL2. Antibody neutralization of CCL2 and CCL7 significantly reduced LPS-induced total leukocyte and neutrophil accumulation, recovered from the bronchoalveolar lavage fluid of challenged mice. Immunohistochemical analysis revealed that CCL2 predominantly localized to alveolar macrophages and pulmonary epithelial cells, whereas CCL7 was restricted to the pulmonary epithelium. In keeping with these observations, the intranasal administration of recombinant CCL2 (rCCL2) and rCCL7 led to the accumulation of neutrophils within the lung airspaces of naive mice in the absence of any underlying inflammation. Flow cytometry analysis further demonstrated an increase in Ly6G(hi) neutrophils expressing the chemokine receptors, CCR1 and CCR2, isolated from mouse lungs compared with circulating neutrophils. Conversely, the expression of CXCR2 decreased on neutrophils isolated from the lung compared with circulating neutrophils. Furthermore, this switch in chemokine receptor expression was accentuated after acute LPS-induced lung inflammation. Collectively, these findings reveal a novel role for PAR1 and the chemokines, CCL2 and CCL7, during the early events of acute neutrophilic inflammation.
PAR1 在介导凝血和炎症之间的相互作用中起着核心作用,但它在调节急性中性粒细胞炎症中的作用尚不清楚。我们报告说,PAR1 拮抗剂在 LPS 诱导的肺炎症小鼠模型中非常有效地减少急性中性粒细胞积聚。PAR1 拮抗剂还减少了这些小鼠的肺泡毛细血管屏障破坏。这种保护与趋化因子 CCL2 和 CCL7 的表达减少有关,但与促炎细胞因子 TNF 和 IL-6 或经典中性粒细胞趋化因子 CXCL1 和 CXCL2 无关。CCL2 和 CCL7 的抗体中和显著减少了 LPS 诱导的总白细胞和中性粒细胞积聚,从 challenged 小鼠的支气管肺泡灌洗液中恢复。免疫组织化学分析显示 CCL2 主要定位于肺泡巨噬细胞和肺上皮细胞,而 CCL7 仅限于肺上皮细胞。与这些观察结果一致,重组 CCL2(rCCL2)和 rCCL7 的鼻腔给药导致在没有任何潜在炎症的情况下,幼稚小鼠肺部气道空间中性粒细胞的积聚。流式细胞术分析进一步表明,与循环中性粒细胞相比,从小鼠肺部分离的 Ly6G(hi)表达趋化因子受体 CCR1 和 CCR2 的中性粒细胞增加。相反,与循环中性粒细胞相比,从肺部分离的中性粒细胞中 CXCR2 的表达减少。此外,这种趋化因子受体表达的转变在急性 LPS 诱导的肺炎症后更加明显。总之,这些发现揭示了 PAR1 和趋化因子 CCL2 和 CCL7 在急性中性粒细胞炎症早期事件中的新作用。